ProQR Therapeutics (PRQR) EBITDA (2013 - 2025)
ProQR Therapeutics recorded quarterly EBITDA of -$10.6 million in Q4 2025, down 182.13% quarter-over-quarter from $12.9 million in Q3 2025, and up 1.7% year-over-year from -$10.4 million in Q4 2024.
ProQR Therapeutics' EBITDA history runs 13 years deep, the most recent figure standing at -$10.6 million for Q4 2025.
- In Q4 2025, EBITDA rose 1.7% year-over-year to -$10.6 million; the TTM figure through Dec 2025 stood at -$23.2 million (down 243.95% YoY), while the FY2025 annual figure was -$47.4 million, down 60.16% from the prior year.
- EBITDA came in at -$10.6 million for Q4 2025 at ProQR Therapeutics, down from $12.9 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $20.7 million in Q4 2021 to a low of -$22.9 million in Q3 2022.
- A 5-year average of -$1.6 million and a median of -$7.4 million in 2023 frame the typical range for EBITDA.
- Across the five-year window, EBITDA jumped 229.14% in 2021 and plunged 618.55% in 2025, its largest moves.
- ProQR Therapeutics' EBITDA stood at $20.7 million in 2021, then tumbled by 161.46% to -$12.7 million in 2022, then surged by 46.95% to -$6.7 million in 2023, then sank by 59.73% to -$10.8 million in 2024, then gained by 1.7% to -$10.6 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$10.6 million, $12.9 million, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | -10.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.59 Mn |
| Sep 30, 2025 | 12.89 Mn |
| Jun 30, 2025 | -14.56 Mn |
| Mar 31, 2025 | -10.99 Mn |
| Dec 31, 2024 | -10.77 Mn |
| Sep 30, 2024 | 9.32 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Mar 31, 2024 | -8.11 Mn |
| Dec 31, 2023 | -6.74 Mn |
| Sep 30, 2023 | 6.26 Mn |
| Jun 30, 2023 | -8.68 Mn |
| Mar 31, 2023 | 9.74 Mn |
| Dec 31, 2022 | -12.71 Mn |
| Sep 30, 2022 | -22.88 Mn |
| Jun 30, 2022 | 13.65 Mn |
| Mar 31, 2022 | 15.59 Mn |
| Dec 31, 2021 | 20.69 Mn |
| Sep 30, 2021 | 17.53 Mn |
| Jun 30, 2021 | -19.14 Mn |
| Mar 31, 2021 | -14.74 Mn |
| Dec 31, 2020 | -16.02 Mn |
| Sep 30, 2020 | 15.70 Mn |
| Jun 30, 2020 | -4.69 Mn |
| Mar 31, 2020 | -17.47 Mn |
| Dec 31, 2019 | -19.29 Mn |
| Sep 30, 2019 | -14.96 Mn |
| Jun 30, 2019 | -13.30 Mn |
| Mar 31, 2019 | -16,176.50 |
| Dec 31, 2018 | -14.83 Mn |
| Sep 30, 2018 | -6,974.12 |
| Jun 30, 2018 | -9.15 Mn |
| Mar 31, 2018 | 13,198.13 |
| Dec 31, 2017 | 13.27 Mn |
| Sep 30, 2017 | 12,305.26 |
| Jun 30, 2017 | -11.19 Mn |
| Mar 31, 2017 | 10.59 Mn |
| Dec 31, 2016 | -9.54 Mn |
| Sep 30, 2016 | -11.30 Mn |
| Jun 30, 2016 | -11.26 Mn |
| Mar 31, 2016 | -9.72 Mn |
| Dec 31, 2015 | -6.71 Mn |
| Sep 30, 2015 | -7.03 Mn |
| Jun 30, 2015 | -9.53 Mn |
| Mar 31, 2015 | -7.62 Mn |
| Dec 31, 2014 | -2.55 Mn |
| Sep 30, 2014 | -4.48 Mn |
| Mar 31, 2014 | -2.54 Mn |
| Dec 31, 2013 | -2.22 Mn |
| Sep 30, 2013 | -1.16 Mn |